Am I seeing this differently to the derampers20 Aug 2021 18:16
The RNS said yesterday
Loss on ordinary activities (after taxation) for the year ended 30th June 2021 is expected to be approximately £1.6 million (2020 loss of £0.96m), reflecting the increased R + D expenditure for preclinical development.
Is it just me but I see the 'loss' as a necessary expenditure to move forward to expedite preclinical trials. So in my book that's an investment and an actual in time working asset.
And we have more cash in the bank after investment post end of June. I'm scratching my head here. I can't see what wasn't expected in the update but good news but it seems to have been utilised as a means to have a 'worthy' reason to cause concern and a couple days out for the wombles.
Am I alone thinking this?